Ceapro inc.: departure of mr. mark redmond, ph.d. as president & ceo of ceapro
discuss this article
EDMONTON, ALBERTA (MARKET WIRE) Ceapro Inc. (TSX VENTURE: CZO) The Company regrets to inform shareholders that Mr. Mark Redmond, Ph.D has decided to step down as a Director and an Officer of the Company effective immediately. In the mean time, Mr. Gilles R. Gagnon, an independent Director of the Company will act as President & CEO during the search period for a new CEO. (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 4, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Source Type: news
Protherics plc: protherics plc announces interest in shares
discuss this article
CHESHIRE, UK (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 4, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech PTIL Source Type: news
Protherics plc: protherics plc announces issue of shares
discuss this article
CHESHIRE, UK (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 4, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech PTIL Source Type: news
Southern cross strengthens board
discuss this article
The nursing home group appointed a former nurse to its management board in the wake of its disastrous profits warning earlier in the week (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 4, 2008 Category: Pharmaceuticals Source Type: news
Myriad terminates phase iii alzheimer’s disease therapy
discuss this article
US-based Myriad Genetics has announced that it has discontinued development of tarenflurbil (Flurizan)... more (Source: Pharmaprojects' Pharma R&D Pipeline News)
Source: Pharmaprojects' Pharma R&D Pipeline News - July 4, 2008 Category: Pharmaceuticals Source Type: news
Novexel discontinues mrsa agent
discuss this article
Novexel has discontinued the development of its antibacterial agent, NXL-101 due to adverse events in a Phase I trial... more (Source: Pharmaprojects' Pharma R&D Pipeline News)
Source: Pharmaprojects' Pharma R&D Pipeline News - July 4, 2008 Category: Pharmaceuticals Source Type: news
Ge healthcare's omnipaque helpful as oral contrast agent, technical note reports
discuss this article
Low-osmolar contrast media, such as GE Healthcare's Omnipaque (Iohexol), make effective oral contrast agents for abdominal CT scans concluded a technical note written by a team of physicians from Johns Hopkins Medical and published in the March/April 2008 edition of the Journal of Computed Assisted Tomography. "It [Low-osmolar contrast media] is relatively non-absorbable and of low risk to the patient if aspirated," according to the technical note. (Source: Pharma Industry News From Medical News Today)
Source: Pharma Industry News From Medical News Today - July 4, 2008 Category: Pharmaceuticals Source Type: news
Novelty of treatment for the masses
discuss this article
Sixty years ago tomorrow Aneurin Bevan symbolically conveyed the keys to the National Health Service to what is now Trafford General Hospital and declared it open. It... (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 3, 2008 Category: Pharmaceuticals Source Type: news
Gps angry at cartel accusation
discuss this article
A drive to turn patients' right to choose their GP into a reality was launched yesterday by health ministers, triggering a fresh clash with the British Medical... (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 3, 2008 Category: Pharmaceuticals Source Type: news
Shire pays out £260m for jerini
discuss this article
The FTSE 100 specialist pharmaceuticals company has widened its footprint in human genetic therapies with the acquisition of the German biotechnology group (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 3, 2008 Category: Pharmaceuticals Source Type: news
Software firm focuses on not-so-blind dates
discuss this article
Think of Ideapoint 19 an online matchmaker bringing biotech inventors and biopharma companies together. In one corner, toiling away in academic... (Source: Investor's Business Daily: HEALTH)
Source: Investor's Business Daily: HEALTH - July 3, 2008 Category: Pharmaceuticals Tags: Health & Medicine Source Type: info
Bad news for competitor turns into good news for celgene
discuss this article
Celgene's stock movement last week had a familiar ring to it, only this time with a different twist. (Source: Investor's Business Daily: HEALTH)
Source: Investor's Business Daily: HEALTH - July 3, 2008 Category: Pharmaceuticals Tags: Health & Medicine Source Type: info
Orbid corporation: orbid corporation and datalase settle patent infringement case
discuss this article
SAN FRANCISCO, CA (MARKET WIRE) ORBID Corporation, Inc., a leading provider of fingerprint/Unique Identity (UID) solutions for cost-effectively and securely guaranteeing the authenticity and integrity of products, today announced they have reached a settlement agreement with DataLase, Ltd. related to patents on ORBID's 2DMI technology. As a result, ORBID is withdrawing its case against DataLase, while continuing to pursue the case against FractureCode, a division of Filtrona PLC. (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 3, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Computers and Software Medical and Healthcare Professional Services Manufacturing and Production Source Type: news
Xechem international inc.: xechem international announces conference call to address information update
discuss this article
EDISON, NJ (MARKET WIRE) Xechem International (PINKSHEETS: XKEM) today announced today that it will be holding a conference call to update shareholders and other interested persons on its business operations and financial status. Details for the call are: (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 3, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare XKEM Source Type: news
Bioheart, inc., board appoints howard j. leonhardt chief executive officer
discuss this article
SUNRISE, Fla., July 3 (HSMN NewsFeed) -- Bioheart, Inc., (Nasdaq: BHRT ) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today anno... Regenerative Medicine, Cardiology, PersonnelBioheart (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2008 Category: Pharmaceuticals Source Type: news
Free vaccine inc.: givevaccines.org creates quiz web site to donate life-saving vaccines to impoverished children around the world through the gavi alliance
discuss this article
ORANGE, CA (MARKET WIRE) Free Vaccine Inc., a non-profit organization dedicated to raising awareness about vaccine-preventable diseases and empowering individuals to be a part of the solution, has launched www.GiveVaccines.org. The site features a fast-paced vocabulary quiz focusing on word roots, English words and medical terminology. For every correct answer, GiveVaccines.org will donate .01 milliliter (ml) of life-saving vaccine to the GAVI Alliance vaccine program. (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 3, 2008 Category: Pharmaceuticals Tags: Education and Training Pharmaceuticals and Biotech Computers and Software Medical and Healthcare Professional Services Retail Media and Entertainment Lifestyle and Leisure Source Type: news
Booktalk: dr. eamonn quigley reveals crucial health benefits of taking probiotics
discuss this article
LOS ANGELES, CA (MARKET WIRE) According to gastroenterologist and President of World Gastroenterology Organization Dr. Eamonn Quigley, your overall health depends on the healthy functioning of your digestive system. Your digestive system not only pulls nutrients from food to nourish the body, but it participates in protecting it from disease. The bacteria that populate the digestive tract play a critical role in both of these functions. (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 3, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare Source Type: news
Medivation to host conference call at 5 p.m. edt monday to discuss
top-line phase 2 study results in huntington's disease
discuss this article
SAN FRANCISCO, July 03, 2008 /PRNewswire-FirstCall/ --
Medivation, Inc. today announced that it will hold a teleconference
at 5:00 p.m. EDT on Monday, July 7, to discuss top-line results
from its randomized, double-blind, placebo-controlled Phase... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 3, 2008 Category: Pharmaceuticals Source Type: news
Catalyst screen patients for clinical trial
discuss this article
Catalyst Pharmaceutical Partners said it has begun enrollment for its U.S. Phase II clinical trial of a treatment for patients addicted to methamphetamine. (CPRX) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 3, 2008 Category: Pharmaceuticals Source Type: journals
Wyeth pharmaceuticals-progenics drug relistor ok'd in europe
discuss this article
Wyeth Pharmaceuticals and Progenics Pharmaceuticals Inc. received marketing approval from the European Commission Thursday for Relistor, a treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care. (WYE) (PGNX) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 3, 2008 Category: Pharmaceuticals Source Type: journals
The best medicine for the nhs at 60
discuss this article
As spending growth slows, the health service in all four parts of the UK needs to demonstrate through reform and innovation that it can deliver improvements (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 3, 2008 Category: Pharmaceuticals Source Type: news
Medicago inc.: medicago receives contribution from nrc-irap for seasonal flu vaccine program
discuss this article
QUEBEC CITY, QUEBEC (MARKET WIRE) Medicago Inc. (TSX VENTURE: MDG) today announced it has been awarded a non-refundable contribution of up to $279,700 from Canada's National Research Council Industrial Research Assistance Program ("NRC-IRAP") to support the development of the Company's seasonal influenza Virus-Like Particles (VLP) vaccine program. Medicago is developing a seasonal vaccine based on its proprietary VLP manufacturing technology, which has the potential to offer speed and cost advantages over competitive technologies. (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 3, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech MDG Source Type: news
Perkinelmer opens center to research stem cells from umbilical cords
discuss this article
PerkinElmer Inc. has created a center dedicated to researching the potential uses of stem cells taken from umbilical cords, the company said Thursday. (PKI) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 3, 2008 Category: Pharmaceuticals Source Type: journals
Shire to buy jerini of germany for $518m
discuss this article
Shire Ltd. entered into a deal Thursday to buy Jerini AG, a German biotechnology company, for $518 million. (SHPGY) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 3, 2008 Category: Pharmaceuticals Source Type: journals
Phase iii ariser study with rencarex: patient recruitment
successfully completed
discuss this article
MUNICH, Germany, July 3,2008- Munich-based biopharmaceutical
company WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange /
Prime Standard) today announced that it has successfully completed
patient recruitment in the Phase III ARISER trial with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 3, 2008 Category: Pharmaceuticals Source Type: news
Studies of adolor-glaxosmithkline's entereg can resume
discuss this article
The Food and Drug Administration said Thursday that clinical studies of Entereg as a treatment for chronic bowel dysfunction such as constipation related to use of opioid painkillers can resume. (ADLR) (GSK) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 3, 2008 Category: Pharmaceuticals Source Type: journals
Blood vessel inhibitor shows promise against metastatic thyroid
cancer researchers also find evidence tying a genetic mutation to
clinical outcome
discuss this article
HOUSTON, July 2, 2008 - Thyroid cancer that has
spread to distant sites has a poor prognosis, but an experimental
drug that inhibits tumor blood vessel formation can slow disease
progression in some patients, a research team led by... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 3, 2008 Category: Pharmaceuticals Source Type: news
Evotec's evt 101 well tolerated in four week higher repeat dose
safety study
discuss this article
HAMBURG, Germany, July 3, 2008 -Evotec AG (Frankfurt Stock
Exchange: EVT; NASDAQ: EVTC) announced today top-line results of a
double-blind, 4-week Phase Ib study with EVT 101, an orally active
NR2B-subtype selective antagonist of NMDA receptors... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 3, 2008 Category: Pharmaceuticals Source Type: news
Cutting edge information: oncology market to grow to $85 billion by 2013, according to new therapeutic study by cutting edge information
discuss this article
RESEARCH TRIANGLE PARK, NC (MARKET WIRE) The oncology market will grow from $57 billion in 2007 to more than $85 billion in 2013, according to a new report by Cutting Edge Information. (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 3, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare Media and Entertainment Source Type: news
Resolvyx scientific advisors publish first in-vivo data showing
resolvins suppress il-23 and il-17, key mediators of inflammatory
disease
discuss this article
BEDFORD, Mass.--(BUSINESS WIRE)--Jul 3, 2008 - Resolvyx
Pharmaceuticals, Inc., the leading resolvin therapeutics company,
today announced that a research team led by a Resolvyx scientific
advisor and a company co-founder has demonstrated that the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 3, 2008 Category: Pharmaceuticals Source Type: news
Vavelta: phase ii data presented at face and commercial sales
commenced
discuss this article
CAMBRIDGE, England, July 3, 2008-Intercytex Group plc (LSE: ICX)
the leading developer of regenerative medicine products to restore
skin and hair, today announces that positive 6 month follow-up data
from two Phase II trials of VAVELTA, its cell... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 3, 2008 Category: Pharmaceuticals Source Type: news
Edap expands ablatherm-hifu business in germany
discuss this article
LYON, France, July 3, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today it has entered into two new revenue per procedure (RPP) contracts in Germany with St. Barbara Hospital in Gladbeck and the Urological Clinic of the University of Heidelberg. (Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - July 3, 2008 Category: Pharmaceuticals Source Type: news
New research indicates that adrenal nodules not being adequately
evaluated
discuss this article
BOSTON--(BUSINESS WIRE)--Jul 2, 2008 - A new study published in
Endocrine Practice found that a substantial percentage of patients
with nodules, or growths, in their adrenal glands were not being
properly evaluated by physicians.
Adrenal glands are... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 3, 2008 Category: Pharmaceuticals Source Type: news
P&g quits collaboration with aryx therapeutics
discuss this article
Aryx Therapeutics Inc. said Wednesday that Procter & Gamble Pharmaceuticals Inc. is exercising an option to end its collaboration with the company on development of a drug for chronic constipation and indigestion. (PG) (ARYX) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 3, 2008 Category: Pharmaceuticals Source Type: journals
Aryx therapeutics, inc. announces successful results of qt study on
ati-7505
discuss this article
FREMONT, Calif.--(BUSINESS WIRE)--Jul 2, 2008 - ARYx Therapeutics,
Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced
the results of an important cardiac safety study on its prokinetic
agent, ATI-7505. The overall results of a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 3, 2008 Category: Pharmaceuticals Source Type: news
Hls: hls continues to grow
discuss this article
PARSIPPANY, NJ (MARKET WIRE) HLS, the founding CommonHealth medical-education unit, today announced two promotions and four new hires. (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 3, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare WPPGY Source Type: news
The great drug debate
discuss this article
An FDA meeting on diabetes provides a window into controversies that are shaking the drug industry. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 3, 2008 Category: Pharmaceuticals Source Type: news
Ms drug development agreement based on wehi's medicinal chemistry
discuss this article
Research conducted at The Walter and Eliza Hall Institute (WEHI) has contributed significantly to a major licensing agreement signed between Australian biotechnology company, Bionomics, (ASX:BNO) and Germany- based pharmaceutical company, Merck Serono. Under the Development and Licensing Agreement, Merck Serono will seek to develop new treatments for multiple sclerosis (MS) and other autoimmune conditions. (Source: Pharma Industry News From Medical News Today)
Source: Pharma Industry News From Medical News Today - July 3, 2008 Category: Pharmaceuticals Source Type: news
17.06.08: bayer group: names figures facts
discuss this article
Bayer Group: Names Figures FactsNew: Names Figures Facts 2008 / 2009Link to websiteAll changes (Source: Bayer IR Newsfeed: New on this site)
Source: Bayer IR Newsfeed: New on this site - July 3, 2008 Category: Pharmaceuticals Source Type: news
It benefits from smart shopping
discuss this article
Another day, another acquisition for Almost Family. Or so it seems. Almost Family, a provider of in-home nursing and therapeutic care, has been on... (Source: Investor's Business Daily: HEALTH)
Source: Investor's Business Daily: HEALTH - July 3, 2008 Category: Pharmaceuticals Tags: Health & Medicine Source Type: info
Teva receives first u.s. approval for generic risperdal(r) tablets; commences commercial launch
discuss this article
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Janssen's antipsychotic agent Risperdal® (Risperidone) Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. Shipment of these products has commenced. (Source: Pharma Industry News From Medical News Today)
Source: Pharma Industry News From Medical News Today - July 3, 2008 Category: Pharmaceuticals Source Type: news
Canadian business groups applaud bold, competitive vision set out by competition policy review panel
discuss this article
A broad coalition of Canadian business groups welcomes the bold vision and ambitious scope of the final report of the Competition Policy Review Panel and calls on the federal government to secure the economic future of all Canadians by acting quickly on the report's recommendations. (Source: Pharma Industry News From Medical News Today)
Source: Pharma Industry News From Medical News Today - July 3, 2008 Category: Pharmaceuticals Source Type: news
Skyepharma plc: skyepharma plc announces research update
discuss this article
LONDON (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech)
Source: Market Wire - Pharmaceuticals and Biotech - July 3, 2008 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Chemicals SKP SKYE Source Type: news
Professor defends research on fda
discuss this article
A Harvard University professor defended research suggesting the FDA was making overly hasty approval decisions on medicines, an analysis the agency has criticized as mistaken. (Source: WSJ.com: Health)
Source: WSJ.com: Health - July 3, 2008 Category: Pharmaceuticals Source Type: news
Unitedhealth lowers outlook, settles lawsuits
discuss this article
UnitedHealth Group slashed its full-year earnings outlook on Wednesday because of tough competition in the health benefits business and said it would pay more than $900 million to settle lawsuits related to past stock options practices. Reuters Health Information (Source: Medscape Business of Medicine Headlines)
Source: Medscape Business of Medicine Headlines - July 2, 2008 Category: Pharmaceuticals Tags: Business of Medicine Source Type: info
Unitedhealth settles suits
discuss this article
UnitedHealth agreed to pay more than $900 million to resolve shareholder lawsuits stemming from an options-backdating case. (Source: WSJ.com: Health)
Source: WSJ.com: Health - July 2, 2008 Category: Pharmaceuticals Source Type: news
Upgrade of diabetes-drug standards urged
discuss this article
An FDA panel of outside medical experts said the agency should raise standards for approving diabetes drugs, a move that could affect the $5 billion-plus diabetes drug market in the U.S. (Source: WSJ.com: Health)
Source: WSJ.com: Health - July 2, 2008 Category: Pharmaceuticals Source Type: news
Nhs celebrations clouded by threat to founding principles
discuss this article
As Britain's tax-funded National Health Service prepares to celebrate its 60th birthday on Saturday, an overwhelming majority of those who use the system fear its core... (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 2, 2008 Category: Pharmaceuticals Source Type: news
Ashley house up despite sales fall
discuss this article
Ashley House, which manages the construction of medical centres and doctors' surgeries for the National Health Service, increased annual profits in spite of a fall in... (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 2, 2008 Category: Pharmaceuticals Source Type: news
Legal decision boosts astrazeneca
discuss this article
Shares in AstraZeneca rose nearly 5 per cent on Wednesday after a US legal ruling pushed back the likely launch of a generic version of Seroquel, its blockbuster schizophrenia medicine, until 2011 (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 2, 2008 Category: Pharmaceuticals Source Type: news
